IMUX Q4 2019 Earnings — Immunic, Inc. Revenue & Financial Results | Market Cap Arena

IMUXImmunic, Inc.

$138M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$8M

Net Income

-$8M

EPS (Diluted)

$-0.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$330,000

Balance Sheet

Total Assets

$66M

Total Liabilities

$8M

Stockholders' Equity

$58M

Cash & Equivalents

$29M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$8M	-$3M	-220.9%
Net Income	-$8M	-$2M	-212.1%